MedTrace Logo

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

NCT04784000 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-07-29

No results posted yet for this study

Summary

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

Period 1: AT-527 550 mg

AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1

DRUG

Period 2: carbamazepine

Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25

DRUG

Period 3: AT-527 550 mg + carbamazepine

AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

DRUG

Period 3: AT-527 1100 mg + carbamazepine

AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-04-10
Completion
2021-04-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04784000 on ClinicalTrials.gov